Presentation AHA 2024

Randomized Study Comparing PK/PD Properties of a Novel Intranasal Formulation of Bumetanide to Oral and IV Formulations

Presenter: Daniel Bensimhon

November 18, 2024

REGISTER for free or LOG IN to view this content

Randomized Study Comparing PK/PD Properties of a Novel Intranasal Formulation of Bumetanide to Oral and IV Formulations

Heart Failure

Heart Failure Pharma

Presentation

AHA 2024

Up Next

Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

More slides +

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.